Nano TransMed最新文献

筛选

英文中文

Evoking pyroptosis with nanomaterials for cancer immunotherapy: Current boom and novel outlook 纳米材料在肿瘤免疫治疗中的应用：现状与展望

Nano TransMed Pub Date : 2022-03-01 DOI: 10.26599/NTM.2022.9130001

Wen-Da Wang , Zhi-Jun Sun

{"title":"Evoking pyroptosis with nanomaterials for cancer immunotherapy: Current boom and novel outlook","authors":"Wen-Da Wang , Zhi-Jun Sun","doi":"10.26599/NTM.2022.9130001","DOIUrl":"10.26599/NTM.2022.9130001","url":null,"abstract":"<div><h3>ABSTRACT</h3><div>Cancer immunotherapy, including immune checkpoint blockade, has emerged as a powerful and effective clinical strategy for the treatment of tumors. However, the low response rates or systemic adverse effects owing to the heterogeneity of the tumor microenvironment limit the efficacy of cancer immunotherapy. Pyroptosis, featuring inflammation and lysis, can promote the release of large amounts of proinflammatory agents that reprogram the tumor microenvironment and is expected to achieve the transition from “cold” tumors to “hot” tumors. Therefore, understanding how to particularly evoke tumor cell pyroptosis is crucial in overcoming the adverse effects associated with the tumor microenvironment. The development of emerging nanotechnology offers an avenue for tumor-targeted drug development. Nanomaterials that can trigger tumor-specific pyroptosis have promising applications in improving the efficacy of cancer immunotherapy while reducing systemic adverse effects. Herein, we review the fundamentals of pyroptosis, and summarize the strategies of pyroptosis-based nanomaterials that have been developed recently, with emphasis on their utility and benefits in cancer immunotherapy. Furthermore, we put forth our viewpoints regarding the investigation of nanomaterials and suggest future directions for this rapidly developing field.</div></div>","PeriodicalId":100941,"journal":{"name":"Nano TransMed","volume":"1 1","pages":"Article e9130001"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78678655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy and safety of bisphosphonate therapy for bone loss in individuals after middle age: A systematic review and network meta-analysis 双膦酸盐治疗中年人骨质流失的比较疗效和安全性：一项系统综述和网络荟萃分析

Nano TransMed Pub Date : 2022-03-01 DOI: 10.26599/NTM.2022.9130003

Qin Hu , Xun Pan , Yaxian Liang , Hongdan Xu , Jinning Gu , Wenting She , Huixu Xie

{"title":"Comparative efficacy and safety of bisphosphonate therapy for bone loss in individuals after middle age: A systematic review and network meta-analysis","authors":"Qin Hu , Xun Pan , Yaxian Liang , Hongdan Xu , Jinning Gu , Wenting She , Huixu Xie","doi":"10.26599/NTM.2022.9130003","DOIUrl":"10.26599/NTM.2022.9130003","url":null,"abstract":"<div><div><strong>PURPOSE:</strong> The purpose of this study was to estimate the benefits and drawbacks of bisphosphonates in the treatment of osteoporosis and osteopenia in middle-aged and elderly individuals.</div><div><strong>METHODS:</strong> We searched Ovid MEDLINE, Embase, the Web of Science, and Cochrane library databases for randomized clinical trials (RCTs) evaluating the effects of bisphosphonates and performed a network meta-analysis to summarize the direct and indirect evidence on the efficacy and safety of bisphosphonate therapy in middle-aged and elderly individuals with osteoporosis or osteopenia.</div><div><strong>RESULTS:</strong> A total of 14 RCTs (7,769 patients with osteoporosis or osteopenia, median age, 67 years, median follow-up, 27 months) were included in this network meta-analysis. Of these, 8, 10, 9, and 6 RCTs provided outcomes on bone mineral density changes, clinical fracture rates, vertebral fracture rates, and nonvertebral fracture rates, respectively. Regarding the primary efficacy outcome, there was a 97% probability for alendronate to be the most effective treatment approach for increasing bone mineral density and an 84% probability for zoledronate to be the most effective treatment approach for clinical fractures. Regarding vertebral fractures and safety outcomes, zoledronate showed an odds ratio (OR) of 0.45 (95% confidence intervals [CI], 0.30-0.69) relative to placebo. For nonvertebral fractures, the OR of zoledronate relative to placebo was 0.51 (95% CI 0.29-0.90).</div><div><strong>CONCLUSIONS:</strong> This study revealed that alendronate was effective in increasing bone mineral density in middle-aged individuals and that zoledronate was a safe treatment option for osteoporosis and osteopenia, conferring a low incidence of fracture. However, further clinical studies are needed to confirm these results.</div></div>","PeriodicalId":100941,"journal":{"name":"Nano TransMed","volume":"1 1","pages":"Article e9130003"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74043573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atomic force microscopy: A nanobiotechnology for cellular research 原子力显微镜：用于细胞研究的纳米生物技术

Nano TransMed Pub Date : 2022-03-01 DOI: 10.26599/NTM.2022.9130004

Guangzhao Guan , Yan He , Li Mei

引用次数: 0

首页上一页